Inovio misses Q3 revenues; CSL rebrands its flu vaccines business;

> Inovio ($INO) missed a Q3 consensus revenue estimate of $29 million from Zack's, instead bringing in $24.2 million. Earnings report

> CSL announced that its flu vaccines business will operate under the brand Seqirus. Release

> France-based Valneva's U.S. subsidiary, Intercell USA, has entered into a distribution and marketing services agreement with VaxServe, a Sanofi Pasteur company, for Valneva's Japanese encephalitis vaccine. Release

> Researchers at Washington University in St. Louis have identified broadly neutralizing antibodies that protect against infection from a range of alphaviruses, including Chikungunya virus. Release

> Caladrius Biosciences ($CLBS) presented additional data at the Society for Immunotherapy of Cancer Annual Meeting supporting its lead candidate for the treatment of metastatic melanoma. Release

Suggested Articles

After countless headlines from a Dengvaxia safety scandal in the Philippines, officials are now considering using the Sanofi vaccine again.

Merck's oncology superstar Keytruda has been stealing the spotlight, but in vaccines, the drugmaker has growth figures to tout.

Experts are pushing for the introduction of J&J's vaccine in the response to the Ebola outbreak in the Democratic Republic of Congo.